Business & Finance
GBT acquires Laboratorio DOSA for USD29.9m
13 November 2017 -

Biopharmaceutical company GBT-Grupo Biotoscana (B3:GBIO33) revealed on Monday that it has completed the acquisition of Laboratorio DOSA for a purchase price of USD29.9m.

Following closing, the acquisition of Laboratorio DOSA will advance GBT's strategic agenda as well as expand its scope into the promising area of severe lung diseases.

GBT said it will seek to capitalise on pulmonary market by further expanding its regional footprint as well as diversifying its product portfolio through in-licensing and proprietary R&D. Severe pulmonary diseases are one of the fastest-growing segment of the global pharmaceutical sector, according to a study by Allied Market Research.

Based in Argentina, Laboratorio DOSA is a specialty pharmaceutical manufacturer and the bulk of its products treat severe pulmonary pathologies. It posted revenues of ARS326m in 2016.